Literature DB >> 15931452

Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome.

F Gutiérrez1, M Masiá, J C Rodríguez, C Mirete, B Soldán, S Padilla, I Hernández, G Royo, A Martin-Hidalgo.   

Abstract

Community-acquired pneumonia (CAP) of mixed etiology has increasingly been appreciated in the literature, but its clinical significance remains unknown. The aim of this analysis was to describe the prevalence, clinical characteristics, and outcome of CAP of mixed etiology. Data were obtained from a 2-year prospective study of consecutive patients with CAP in whom an extensive microbiological workup was performed. Predefined strict criteria were used to establish the etiology. A total of 493 patients were included. A single pathogen was detected in 222 (45%) cases and two or more pathogens in 28 (5.7%) cases. Mixed infections were seen across all age groups and in patients treated both in hospital and as outpatients. The most frequent combinations of pathogens were those of a bacterium plus an "atypical" organism (28.6%) and of two bacterial organisms (28.6%). Compared with patients with monomicrobial pneumonia, patients with mixed pneumonia were more likely to have underlying conditions (64% vs. 45%, p=0.04) and dementia (25% vs. 10%, p=0.02). The incidence of a defined series of complications was higher in patients with mixed pneumonia (39.3% vs. 18.6%; OR=2.84; p=0.02). Community-acquired pneumonia of mixed etiology is uncommon. Patients with mixed pneumonia are more likely to have underlying medical conditions, and they may have a more severe course of disease.

Entities:  

Mesh:

Year:  2005        PMID: 15931452     DOI: 10.1007/s10096-005-1346-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  41 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia.

Authors:  Beatriz Rosón; Nuria Fernández-Sabé; Jordi Carratalà; Ricard Verdaguer; Jordi Dorca; Frederic Manresa; Francesc Gudiol
Journal:  Clin Infect Dis       Date:  2003-12-18       Impact factor: 9.079

3.  Usefulness of urinary antigen detection by an immunochromatographic test for diagnosis of pneumococcal pneumonia in children.

Authors:  J Domínguez; S Blanco; C Rodrigo; M Azuara; N Galí; A Mainou; A Esteve; A Castellví; C Prat; L Matas; V Ausina
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

4.  Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

Authors:  José A Martínez; Juan P Horcajada; Manuel Almela; Francesc Marco; Alex Soriano; Elisa García; Maria Angeles Marco; Antoni Torres; Josep Mensa
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

5.  Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

Authors:  M A Mufson; R J Stanek
Journal:  Am J Med       Date:  1999-07-26       Impact factor: 4.965

6.  Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.

Authors:  P P Gleason; T P Meehan; J M Fine; D H Galusha; M J Fine
Journal:  Arch Intern Med       Date:  1999-11-22

7.  Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.

Authors:  J E Stahl; M Barza; J DesJardin; R Martin; M H Eckman
Journal:  Arch Intern Med       Date:  1999-11-22

8.  Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.

Authors:  G W Waterer; G W Somes; R G Wunderink
Journal:  Arch Intern Med       Date:  2001 Aug 13-27

9.  Chlamydia species as a cause of community-acquired pneumonia in Canada.

Authors:  T J Marrie; R W Peeling; T Reid; E De Carolis
Journal:  Eur Respir J       Date:  2003-05       Impact factor: 16.671

10.  Aetiology of community acquired pneumonia in Valencia, Spain: a multicentre prospective study.

Authors:  J Blanquer; R Blanquer; R Borrás; D Nauffal; P Morales; R Menéndez; I Subías; L Herrero; J Redón; J Pascual
Journal:  Thorax       Date:  1991-07       Impact factor: 9.139

View more
  18 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

2.  Impact of bacterial coinfection on clinical outcomes in pneumococcal pneumonia.

Authors:  S Kumagai; T Ishida; H Tachibana; Y Ito; A Ito; T Hashimoto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-10       Impact factor: 3.267

3.  Thin-section CT findings of patients with acute Streptococcus pneumoniae pneumonia with and without concurrent infection.

Authors:  F Okada; Y Ando; S Matsushita; R Ishii; T Nakayama; K Morikawa; A Ono; T Maeda; H Mori
Journal:  Br J Radiol       Date:  2012-01-03       Impact factor: 3.039

4.  Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China.

Authors:  Zibo Zhou; Xiangzhi Li; Xiaojian Chen; Fangjun Luo; Changwang Pan; Xiaoping Zheng; Feng Tan
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

5.  Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study.

Authors:  Jang Wook Sohn; Seung Chul Park; Young-Hwa Choi; Heung Jeong Woo; Yong Kyun Cho; Jin Soo Lee; Hee-Sun Sim; Min Ja Kim
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 6.  Improving outcomes of elderly patients with community-acquired pneumonia.

Authors:  Félix Gutiérrez; Mar Masiá
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

7.  Etiology of community-acquired pneumonia in a population-based study: link between etiology and patients characteristics, process-of-care, clinical evolution and outcomes.

Authors:  Alberto Capelastegui; Pedro P España; Amaia Bilbao; Julio Gamazo; Federico Medel; Juan Salgado; Iñaki Gorostiaga; Maria Jose Lopez de Goicoechea; Inmaculada Gorordo; Cristobal Esteban; Lander Altube; Jose M Quintana
Journal:  BMC Infect Dis       Date:  2012-06-12       Impact factor: 3.090

Review 8.  Chlamydia psittaci (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis.

Authors:  L Hogerwerf; B DE Gier; B Baan; W VAN DER Hoek
Journal:  Epidemiol Infect       Date:  2017-09-26       Impact factor: 4.434

9.  Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis.

Authors:  Catia Cillóniz; Santiago Ewig; Miquel Ferrer; Eva Polverino; Albert Gabarrús; Jorge Puig de la Bellacasa; Josep Mensa; Antoni Torres
Journal:  Crit Care       Date:  2011-09-14       Impact factor: 9.097

Review 10.  Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia.

Authors:  Kay Wang; Peter Gill; Rafael Perera; Anne Thomson; David Mant; Anthony Harnden
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.